Jennie W. Taylor MD, MPH

Jennie Taylor MD, neuro-oncologistAssistant Professor of Neurology and Neurological Surgery
Division of Neuro-Oncology

Dr. Taylor specializes in caring for adult patients with primary brain tumors. As a member of the Brain Tumor Center at UCSF, she is involved in the development and execution of novel treatment strategies, innovative imaging techniques, and comprehensive molecular profiling to improve outcomes for patients with brain tumors. She is a co-investigator for brain tumor clinical trials conducted at UCSF, and an active participant in multi-institutional trials collaborating with industry and national consortia. Her research interests include analyzing molecular and imaging markers of resistance to current, standard treatment. She is also focused on improving the quality-of-life for patients with primary brain tumors, as well as their caregivers. Additionally, she teaches and mentors neurology and neurosurgery residents, and hematology-oncology fellows by exposing them to neuro-oncology patients.

Education, Training, and Previous Positions

2001: BS, Randolph-Macon Woman’s College
2007: MD, University of Kentucky College of Medicine
2007 – 2008: Internship, Department of Medicine, University of Virginia
2008 – 2011: Resident, Department of Neurology, University of Virginia
2011 – 2014: Fellow, Neuro-Oncology, Massachusetts General Hospital and Dana-Farber Cancer Institute
2012 – 2014: MPH, Harvard School of Public Health

Selected Professional Memberships and Appointments

American Academy of Neurology
Society for Neuro-Oncology
American Society of Clinical Oncology

Selected Recent Publications

Ellingson BM, Abrey LE, Nelson SJ, Kaufmann TJ, Garcia J, Chinot O, Saran F, Nishikawa R, Henriksson R, Mason WP, Wick W, Butowski N, Ligon KL, Gerstner ER, Colman H, de Groot J, Chang S, Mellinghoff I, Young RJ, Alexander BM, Colen R, Taylor JW, Arrillaga-Romany I, Mehta A, Huang RY, Pope WB, Reardon D, Batchelor T, Prados M, Galanis E, Wen PY, Cloughesy TF. Validation of post-operative residual contrast enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma. Neuro Oncol. 2018 Apr 5. doi: 10.1093/neuonc/noy053. [Epub ahead of print] PubMed PMID: 29660006.

Byron SA, Tran NL, Halperin RF, Phillips JJ, Kuhn JG, de Groot JF, Colman H, Ligon KL, Wen PY, Cloughesy TF, Mellinghoff IK, Butowski NA, Taylor JW, Clarke JL, Chang SM, Berger MS, Molinaro AM, Maggiora GM, Peng S, Nasser S, Liang WS, Trent JM, Berens ME, Carpten JD, Craig DW, Prados MD. Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma. Clin Cancer Res. 2018 Jan 15;24(2):295-305. doi: 10.1158/1078-0432.CCR-17-0963. Epub 2017 Oct 26. PubMed PMID: 29074604.

Wahl M, Chang SM, Phillips JJ, Molinaro AM, Costello JF, Mazor T, Alexandrescu S, Lupo JM, Nelson SJ, Berger M, Prados M, Taylor JW, Butowski N, Clarke JL, Haas-Kogan D. Probing the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in gliomas: A phase 2 study of everolimus for recurrent adult low-grade gliomas. Cancer. 2017 Dec 1;123(23):4631-4639. doi: 10.1002/cncr.30909. Epub 2017 Jul 31. PubMed PMID: 28759109; PubMed Central PMCID: PMC5693663.

Pekmezci M, Rice T, Molinaro AM, Walsh KM, Decker PA, Hansen H, Sicotte H, Kollmeyer TM, McCoy LS, Sarkar G, Perry A, Giannini C, Tihan T, Berger MS, Wiemels JL, Bracci PM, Eckel-Passow JE, Lachance DH, Clarke J, Taylor JW, Luks T, Wiencke JK, Jenkins RB, Wrensch MR. Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT. Acta Neuropathol. 2017 Jun;133(6):1001-1016. doi: 10.1007/s00401-017-1690-1. Epub 2017 Mar 2. PubMed PMID: 28255664; PubMed Central PMCID: PMC5432658.

Clarke JL, Molinaro AM, Cabrera JR, DeSilva AA, Rabbitt JE, Prey J, Drummond DC, Kim J, Noble C, Fitzgerald JB, Chang SM, Butowski NA, Taylor JW, Park JW, Prados MD. A phase 1 trial of intravenous liposomal irinotecan in patients with recurrent high-grade glioma. Cancer Chemother Pharmacol. 2017 Mar;79(3):603-610. doi: 10.1007/s00280-017-3247-3. Epub 2017 Feb 23. PubMed PMID: 28233053.

Ohnishi T, Nakamura Y, Tanaka T, Tanaka T, Hashimoto N, Haneishi H, Batchelor TT, Gerstner ER, Taylor JW, Snuderl M, Yagi Y. Deformable image registration between pathological images and MR image via an optical macro image. Pathol Res Pract. 2016 Oct;212(10):927-936. doi: 10.1016/j.prp.2016.07.018. Epub 2016 Aug 2. PubMed PMID: 27613662; PubMed Central PMCID: PMC5097673.

Chan AK, Birk HS, Winkler EA, Viner JA, Taylor JW, McDermott MW. Stability of Programmable Shunt Valve Settings with Simultaneous Use of the Optune Transducer Array: A Case Report. Cureus. 2016 Jul 7;8(7):e675. doi: 10.7759/cureus.675. PubMed PMID: 27551653; PubMed Central PMCID: PMC4977218.

Kloepper J, Riedemann L, Amoozgar Z, Seano G, Susek K, Yu V, Dalvie N, Amelung RL, Datta M, Song JW, Askoxylakis V, Taylor JW, Lu-Emerson C, Batista A, Kirkpatrick ND, Jung K, Snuderl M, Muzikansky A, Stubenrauch KG, Krieter O, Wakimoto H, Xu L, Munn LL, Duda DG, Fukumura D, Batchelor TT, Jain RK. Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival. Proc Natl Acad Sci U S A. 2016 Apr 19;113(16):4476-81. doi: 10.1073/pnas.1525360113. Epub 2016 Apr 4. PubMed PMID: 27044098; PubMed Central PMCID: PMC4843473.

Endicott AA, Taylor JW, Walsh KM. Telomere length connects melanoma and glioma predispositions. Aging (Albany NY). 2016 Mar;8(3):423-4. PubMed PMID: 27029497; PubMed Central PMCID: PMC4833136.

Han SJ, Englot DJ, Birk H, Molinaro AM, Chang SM, Clarke JL, Prados MD, Taylor JW, Berger MS, Butowski NA. Impact of Timing of Concurrent Chemoradiation for Newly Diagnosed Glioblastoma: A Critical Review of Current Evidence. Neurosurgery. 2015 Aug;62 Suppl 1:160-5. doi: 10.1227/NEU.0000000000000801. Review. PubMed PMID: 26181937; PubMed Central PMCID: PMC5260825.

Lu-Emerson C, Duda DG, Emblem KE, Taylor JW, Gerstner ER, Loeffler JS, Batchelor TT, Jain RK. Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma. J Clin Oncol. 2015 Apr 1;33(10):1197-213. doi: 10.1200/JCO.2014.55.9575. Epub 2015 Feb 23. PubMed PMID: 25713439; PubMed Central PMCID: PMC4517055.

Taylor JW, Dietrich J, Gerstner ER, Norden AD, Rinne ML, Cahill DP, Stemmer-Rachamimov A, Wen PY, Betensky RA, Giorgio DH, Snodgrass K, Randall AE, Batchelor TT, Chi AS. Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma. J Neurooncol. 2015 Feb;121(3):557-63. doi: 10.1007/s11060-014-1667-z. Epub 2014 Nov 20. PubMed PMID: 25411098; PubMed Central PMCID: PMC4323868.

Taylor JW, Schiff D. Treatment considerations for MGMT-unmethylated glioblastoma. Curr Neurol Neurosci Rep. 2015 Jan;15(1):507. doi: 10.1007/s11910-014-0507-z. Review. PubMed PMID: 25394859.